Alterity Therapeutics Receives Positive FDA Feedback for ATH434 Phase 3 Program

Alignment reached on key elements of ATH434 Phase 3 development program

Mar. 30, 2026 at 11:57am by Ben Kaplan

Got story updates? Submit your updates here. ›

Alterity Therapeutics, a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, has received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type C Meeting regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). The meeting confirmed alignment on key elements of the program, including clinical pharmacology and non-clinical development, setting the stage for future discussions on the Phase 3 trial design and Chemistry, Manufacturing, and Controls (CMC).

Why it matters

The positive feedback from the FDA is an important milestone for Alterity as it prepares to initiate a Phase 3 pivotal trial for ATH434in MSA, a rare and rapidly progressive neurodegenerative disorder. The alignment reached on key elements of the development program provides a clear path forward and increases the likelihood of a successful Phase 3 trial, which could lead to a potential new treatment option for patients suffering from this debilitating condition.

The details

During the Type C Meeting, the FDA provided written feedback supporting Alterity's plans related to the clinical pharmacology and non-clinical development elements of the ATH434 Phase 3 program. The company will also be seeking agreement with the FDA on the Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design. Alterity is preparing to initiate the Phase 3 pivotal trial in MSA, having previously reported positive data from a randomized, double-blind, placebo-controlled Phase 2 clinical trial and an open-label Phase 2 trial in participants with advanced MSA.

  • Alterity is on track to hold an End-of-Phase 2 meeting with the FDA in mid-2026.

The players

Alterity Therapeutics

A clinical-stage biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases, including Multiple System Atrophy (MSA).

David Stamler, M.D.

Chief Executive Officer of Alterity Therapeutics.

U.S. Food and Drug Administration (FDA)

The regulatory agency responsible for approving new drugs and medical treatments in the United States.

Got photos? Submit your photos here. ›

What they’re saying

“This meeting confirms alignment with the FDA in two key disciplines and represents an important step toward initiation of the Phase 3 program.”

— David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics

What’s next

Alterity will be seeking agreement with the FDA on the Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design for ATH434, culminating in an End-of-Phase 2 meeting that remains on track for mid-year 2026.

The takeaway

The positive feedback from the FDA on the key elements of Alterity's ATH434 Phase 3 development program for Multiple System Atrophy represents a significant milestone, providing a clear path forward and increasing the chances of a successful Phase 3 trial that could lead to a new treatment option for patients suffering from this rare and debilitating neurodegenerative disorder.